Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Net Margin (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of Net Margin data on record, last reported at 2670.69% in Q3 2025.

  • For Q3 2025, Net Margin changed N/A year-over-year to 2670.69%; the TTM value through Dec 2025 reached 9899.38%, changed N/A, while the annual FY2023 figure was 3768.28%, 306533.0% down from the prior year.
  • Net Margin reached 2670.69% in Q3 2025 per RVMD's latest filing, up from 21770.49% in the prior quarter.
  • Across five years, Net Margin topped out at 2670.69% in Q3 2025 and bottomed at 21770.49% in Q4 2023.
  • Average Net Margin over 4 years is 2739.28%, with a median of 716.15% recorded in 2022.
  • Peak YoY movement for Net Margin: skyrocketed 262334bps in 2022, then tumbled -2139914bps in 2023.
  • A 4-year view of Net Margin shows it stood at 556.83% in 2021, then skyrocketed by 33bps to 371.34% in 2022, then crashed by -5763bps to 21770.49% in 2023, then surged by 112bps to 2670.69% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 2670.69% in Q3 2025, 21770.49% in Q4 2023, and 2570.55% in Q2 2023.